JP2013534217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534217A5 JP2013534217A5 JP2013521934A JP2013521934A JP2013534217A5 JP 2013534217 A5 JP2013534217 A5 JP 2013534217A5 JP 2013521934 A JP2013521934 A JP 2013521934A JP 2013521934 A JP2013521934 A JP 2013521934A JP 2013534217 A5 JP2013534217 A5 JP 2013534217A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- variant
- antibody
- nacl
- hcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36914810P | 2010-07-30 | 2010-07-30 | |
| US61/369,148 | 2010-07-30 | ||
| PCT/US2011/045524 WO2012015912A1 (en) | 2010-07-30 | 2011-07-27 | Method for purifying active polypeptides or immunocojugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534217A JP2013534217A (ja) | 2013-09-02 |
| JP2013534217A5 true JP2013534217A5 (enExample) | 2014-09-18 |
| JP6061853B2 JP6061853B2 (ja) | 2017-01-18 |
Family
ID=45530485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013521934A Expired - Fee Related JP6061853B2 (ja) | 2010-07-30 | 2011-07-27 | 活性ポリペプチドまたは免疫複合体の精製方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9580461B2 (enExample) |
| EP (3) | EP2613857B1 (enExample) |
| JP (1) | JP6061853B2 (enExample) |
| CN (1) | CN103079666B (enExample) |
| BR (1) | BR112013002334A2 (enExample) |
| CA (1) | CA2806314C (enExample) |
| DK (1) | DK3434346T3 (enExample) |
| ES (2) | ES2678204T3 (enExample) |
| HU (2) | HUE051702T2 (enExample) |
| LT (2) | LT3434346T (enExample) |
| MX (1) | MX342920B (enExample) |
| NO (1) | NO2021030I1 (enExample) |
| PL (1) | PL3434346T3 (enExample) |
| PT (1) | PT3434346T (enExample) |
| SG (3) | SG10202009967TA (enExample) |
| WO (1) | WO2012015912A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| ES2678204T3 (es) | 2010-07-30 | 2018-08-09 | Medimmune, Llc | Método para purificar inmunoconjugados |
| CA2815342A1 (en) * | 2010-10-20 | 2012-04-26 | Medimmune, Llc | Methods for processing inclusion bodies |
| WO2013180647A1 (en) * | 2012-05-31 | 2013-12-05 | Agency For Science, Technology And Research | Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities |
| JP6553515B2 (ja) | 2012-12-20 | 2019-07-31 | メディミューン，エルエルシー | 免疫複合体の製造方法 |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| KR101531479B1 (ko) * | 2014-11-21 | 2015-06-26 | 세원셀론텍(주) | 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법 |
| CN108472360B (zh) * | 2015-04-10 | 2023-01-17 | 阿迪马布有限责任公司 | 从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法 |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| IL265109B2 (en) | 2016-09-13 | 2024-05-01 | Allergan Inc | Stabilized non-protein clostridial toxin compositions |
| US11311628B2 (en) | 2016-10-17 | 2022-04-26 | Duke University | Production of immunotoxin D2C7—(scdsFv)—PE38KDEL |
| MY195529A (en) | 2016-11-18 | 2023-01-30 | Astellas Pharma Inc | Novel Anti-Human MUC1 Antibody Fab Fragment |
| WO2018187388A1 (en) * | 2017-04-04 | 2018-10-11 | Scarab Genomics, Llc | Improved purification of crm 197 from bacteria |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| US20200239575A1 (en) * | 2017-10-06 | 2020-07-30 | University Of Utah Research Foundation | A fusion protein for targeted therapy of autoimmune disease |
| EP3691693A4 (en) * | 2017-10-06 | 2021-08-25 | University Of Utah Research Foundation | FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE |
| WO2019221269A1 (ja) | 2018-05-17 | 2019-11-21 | アステラス製薬株式会社 | 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体 |
| MY205764A (en) * | 2018-10-10 | 2024-11-12 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| EP4051321A4 (en) | 2019-10-30 | 2023-11-22 | Duke University | IMMUNOTHERAPY WITH COMBINATION THERAPY INCLUDING AN IMMUNOTOXIN |
| IL295143B2 (en) | 2020-02-13 | 2026-02-01 | Hoffmann La Roche | A method for determining the loading state of AAV particles using nuclear magnetic resonance relaxometry |
| CN115996940A (zh) * | 2020-07-01 | 2023-04-21 | 免疫医疗有限责任公司 | 用于纯化生物治疗剂的洗涤剂和方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| EP0531434B1 (en) | 1990-05-11 | 1999-07-14 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| AU675440B2 (en) | 1992-06-18 | 1997-02-06 | United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant (pseudomonas) exotoxin with increased activity |
| DE69838979T2 (de) | 1997-03-20 | 2008-12-24 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren |
| US6296843B1 (en) | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| CA2461351C (en) | 2001-09-26 | 2014-08-05 | Ira H. Pastan | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
| AU2002361390A1 (en) * | 2001-12-14 | 2003-06-30 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| JP2004089182A (ja) * | 2002-06-24 | 2004-03-25 | Takeda Chem Ind Ltd | がんの予防・治療剤 |
| LT1543038T (lt) * | 2002-09-11 | 2017-07-10 | Genentech, Inc. | Baltymo gryninimas |
| ES2343965T3 (es) | 2003-11-25 | 2010-08-13 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Anticuerpos anti-cd22 e inmunocongujados mutados. |
| US20080125363A1 (en) | 2004-12-14 | 2008-05-29 | Enzon Pharmaceuticals Inc. | Polymer-Linked Pseudomonas Exotoxin Immunotoxin |
| WO2007016150A2 (en) | 2005-07-29 | 2007-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Mutated pseudomonas exotoxins with reduced antigenicity |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| AU2007300221A1 (en) * | 2006-09-25 | 2008-04-03 | Medimmune, Llc. | Stabilized antibody formulations and uses thereof |
| EP2197903B9 (en) | 2007-09-04 | 2015-04-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| WO2009149281A1 (en) * | 2008-06-04 | 2009-12-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxins and uses thereof |
| WO2010045495A2 (en) * | 2008-10-16 | 2010-04-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
| ES2678204T3 (es) | 2010-07-30 | 2018-08-09 | Medimmune, Llc | Método para purificar inmunoconjugados |
-
2011
- 2011-07-27 ES ES11813105.1T patent/ES2678204T3/es active Active
- 2011-07-27 CA CA2806314A patent/CA2806314C/en active Active
- 2011-07-27 MX MX2013001044A patent/MX342920B/es active IP Right Grant
- 2011-07-27 EP EP11813105.1A patent/EP2613857B1/en active Active
- 2011-07-27 BR BR112013002334A patent/BR112013002334A2/pt not_active IP Right Cessation
- 2011-07-27 HU HUE18174165A patent/HUE051702T2/hu unknown
- 2011-07-27 EP EP18174165.3A patent/EP3434346B1/en active Active
- 2011-07-27 PT PT181741653T patent/PT3434346T/pt unknown
- 2011-07-27 SG SG10202009967TA patent/SG10202009967TA/en unknown
- 2011-07-27 WO PCT/US2011/045524 patent/WO2012015912A1/en not_active Ceased
- 2011-07-27 EP EP20192591.4A patent/EP3797847A1/en not_active Withdrawn
- 2011-07-27 ES ES18174165T patent/ES2836447T3/es active Active
- 2011-07-27 CN CN201180037262.XA patent/CN103079666B/zh not_active Expired - Fee Related
- 2011-07-27 JP JP2013521934A patent/JP6061853B2/ja not_active Expired - Fee Related
- 2011-07-27 US US13/813,083 patent/US9580461B2/en not_active Expired - Fee Related
- 2011-07-27 PL PL18174165T patent/PL3434346T3/pl unknown
- 2011-07-27 LT LTEP18174165.3T patent/LT3434346T/lt unknown
- 2011-07-27 SG SG2013005228A patent/SG187587A1/en unknown
- 2011-07-27 SG SG10201506030RA patent/SG10201506030RA/en unknown
- 2011-07-27 DK DK18174165.3T patent/DK3434346T3/da active
-
2017
- 2017-02-03 US US15/423,928 patent/US10072083B2/en active Active
-
2018
- 2018-09-07 US US16/124,441 patent/US10556955B2/en not_active Expired - Fee Related
-
2020
- 2020-02-10 US US16/786,634 patent/US11136396B2/en not_active Expired - Fee Related
-
2021
- 2021-07-14 HU HUS2100027C patent/HUS2100027I1/hu unknown
- 2021-07-15 NO NO2021030C patent/NO2021030I1/no unknown
- 2021-07-29 LT LTPA2021517C patent/LTPA2021517I1/lt unknown
- 2021-09-02 US US17/465,092 patent/US20210395370A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2013121353A5 (enExample) | ||
| JP2019194195A (ja) | 抗ｐｄｌ１抗体製剤 | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| JP2014509835A5 (enExample) | ||
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| IL299072A (en) | Antibodies and methods for using them | |
| HRP20200887T1 (hr) | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa | |
| JP2013538553A5 (enExample) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| HRP20190486T1 (hr) | Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| JP2015525791A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2016536342A5 (enExample) | ||
| JP2016538876A5 (enExample) | ||
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| RU2018135371A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| PE20221447A1 (es) | Anticuerpos anti-tgf-beta 1 latente y metodos de uso | |
| US11401343B2 (en) | Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same | |
| JP2020522280A5 (enExample) |